ono 1078 has been researched along with Mucopolysaccharidosis IV in 1 studies
pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist
Mucopolysaccharidosis IV: Genetic disorder of mucopolysaccharide metabolism characterized by skeletal abnormalities, joint instability, development of cervical myelopathy, and excessive urinary keratan sulfate. There are two biochemically distinct forms, each due to a deficiency of a different enzyme.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alméciga-Diaz, CJ | 1 |
| Hidalgo, OA | 1 |
| Olarte-Avellaneda, S | 1 |
| Rodríguez-López, A | 1 |
| Guzman, E | 1 |
| Garzón, R | 1 |
| Pimentel-Vera, LN | 1 |
| Puentes-Tellez, MA | 1 |
| Rojas-Rodriguez, AF | 1 |
| Gorshkov, K | 1 |
| Li, R | 1 |
| Zheng, W | 1 |
1 other study available for ono 1078 and Mucopolysaccharidosis IV
| Article | Year |
|---|---|
Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
Topics: Catalytic Domain; Chondroitinsulfatases; Chromones; Enzyme Inhibitors; Ezetimibe; Fibroblasts; HEK29 | 2019 |